Danaher (DHR) Could Be 9% Undervalued Following Its CEO Transition News

Simply Wall St.08-12

Danaher (DHR) is back in focus after announcing that Julie Sawyer Montgomery will become CEO and President on October 1, 2026, with outgoing CEO Rainer Blair staying on temporarily as senior advisor. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2658973600?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","is_english":true,"pubTime":"2026-08-12 16:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658973600","market":"sg","top_or_hot":-1,"title":"Danaher (DHR) Could Be 9% Undervalued Following Its CEO Transition News","media":"Simply Wall St.","content":"<div>\n<p>Danaher (DHR) is back in focus after announcing that Julie Sawyer Montgomery will become CEO and President on October 1, 2026, with outgoing CEO Rainer Blair staying on temporarily as senior advisor. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-could-be-9-undervalued-following-its-ceo-transit\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Danaher (DHR) Could Be 9% Undervalued Following Its CEO Transition News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDanaher (DHR) Could Be 9% Undervalued Following Its CEO Transition News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-12 16:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-could-be-9-undervalued-following-its-ceo-transit><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Danaher (DHR) is back in focus after announcing that Julie Sawyer Montgomery will become CEO and President on October 1, 2026, with outgoing CEO Rainer Blair staying on temporarily as senior advisor. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-could-be-9-undervalued-following-its-ceo-transit\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001176.SGD","symbol_name":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-could-be-9-undervalued-following-its-ceo-transit","article_id":"2658973600","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-could-be-9-undervalued-following-its-ceo-transit","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2658973600","pubTimestamp":1786523643,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Danaher (DHR) is back in focus after announcing that Julie Sawyer Montgomery will become CEO and President on October 1, 2026, with outgoing CEO Rainer Blair staying on temporarily as senior advisor.\nSee our latest analysis for Danaher.\nAgainst the leadership news backdrop, Danaher's share price has risen over the past week and quarter, with a 7 day share price return of 6.5% and a 90 day share price return of 25.0%. However, the year to date share price return is down 10.0% and the 5 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","FMED":"Fidelity Disruptive Medicine ETF","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","BK4121":"生命科学工具和服务","LU2063271972.USD":"富兰克林创新领域基金","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU2125910336.SGD":"Natixis Thematics Water R/A SGD","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","DHR":"丹纳赫","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4504":"桥水持仓","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4588":"碎股","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4581":"高盛持仓","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","DHR.AU":"Dark Horse Resources"},"translate_title":"丹纳赫 (DHR) 首席执行官换届消息传出后，估值可能被低估 9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DHR":1.5,"DHR.AU":1.5,"FMED":0.6},"content_text":"Danaher (DHR) is back in focus after announcing that Julie Sawyer Montgomery will become CEO and President on October 1, 2026, with outgoing CEO Rainer Blair staying on temporarily as senior advisor. See our latest analysis for Danaher. Against the leadership news backdrop, Danaher's share price has risen over the past week and quarter, with a 7 day share price return of 6.5% and a 90 day share price return of 25.0%. However, the year to date share price return is down 10.0% and the 5 year total shareholder return is down 25.3%, which suggests recent momentum has picked up after a weaker longer term trend. If this kind of leadership change has you thinking about what else might be setting up for a shift, it could be a useful moment to scan 43 healthcare AI stocks. After Danaher’s recent rebound, the stock now sits about 9% below both the average analyst price target and one estimate of intrinsic value. The key question is whether that gap still represents a genuine discount once the valuation is unpacked. AdvertisementMost Popular Narrative: 9.3% Undervalued Danaher is trading at $207.44 compared with a widely followed narrative fair value of about $228.61, which frames the recent rebound as only part of the story.  The sustained advancement of precision medicine and personalized therapies, including new AI-assisted diagnostic solutions and groundbreaking launches in genomics (like support for in vivo CRISPR therapies), positions Danaher's technology portfolio to capture higher-margin growth and drive long-term EBITDA expansion.  Read the complete narrative. Want to see the engine behind that fair value gap? Revenue expectations, margin uplift and a reset future earnings multiple all sit at the core. Curious which assumptions really move the needle for Danaher’s valuation? Result: Fair Value of $228.61 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Danaher’s story still carries real execution risk, particularly if bioprocessing demand remains soft or if changes to China’s reimbursement and procurement policies continue to pressure diagnostics revenue and margins. Find out about the key risks to this Danaher narrative. Next Steps Given the mix of optimism and concern around Danaher, it makes sense to look at the full picture and not just the headlines. To see the balance between potential upside and the issues investors are watching, check out the 3 key rewards and 1 important warning sign. Looking for more investment ideas beyond Danaher? If Danaher's story has you thinking bigger about your portfolio, do not stop here. Use fresh data driven stock ideas to keep your watchlist sharp and future focused.  Target steadier potential returns by checking companies screened for resilience through the 85 resilient stocks with low risk scores. Hunt for potential mispriced opportunities by reviewing the screener containing 20 high quality undiscovered gems before others catch on. Strengthen your core holdings with companies filtered using the solid balance sheet and fundamentals stocks screener (50 results).   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2658973600","isCrawlerRequest":true}